Annovis Bio, Inc.

ANVS

Exchange: NYSE
Industry: Pharmaceutical Preparations
SEC CIK: 0001477845

SEC filings (opens in a new tab)

In the last 90 days, Annovis Bio, Inc. insiders filed 1 open-market purchase and 0 sales; 61 institutions reported holding it in 13F filings for Q2 2026, worth $20.2M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026: $39.5M
Insider buysLast 90 days, $5.00M in total: 1
Insider sellsOpen market, last 90 days: 0
13F holdersQ2 2026, +5 vs. previous quarter: 61
13F valueReported value at the end of Q2 2026: $20.2M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $0; No comparable prior period
Net income, FY2025: -$28.9M; No comparable prior period
Free cash flow, FY2025: –; No comparable prior period
Revenue, Q3 FY2026: $0; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 5.36M; Shares sold short
Change: −364.8K; −6.4% vs. previous
Days to cover: 6.77; At average daily volume

Superinvestors holding ANVS, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ANVS at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Annovis Bio, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Nov 6, 2026 (view filing)4:30 PM ET	Nov 6	Same day	Hoffman Michael BDirector	PPurchase	+5.00M	$1.00	+$5.00M	+148.6%8.36M after
Nov 6, 2026 (view filing)4:30 PM ET	Nov 6	Same day	Hoffman Michael BDirector	PPurchase	+5.00M	$0.00	$0	–5.00M after	Derivative
May 21, 2026 (view filing)	May 20	1 day	Hoffman Michael BDirector	PPurchase	+76.3K	$1.87	+$142.8K	+2.3%3.36M after	3 lots
Apr 3, 2026 (view filing)	Apr 2	1 day	Hoffman Michael BDirector	PPurchase	+713.8K	$2.10	+$1.50M	+27.7%3.29M after
Dec 8, 2025 (view filing)	Dec 8	Same day	Hoffman Michael BDirector	PPurchase	+45.0K	$4.31	+$193.8K	+1.8%2.57M after	2 lots
Nov 25, 2025 (view filing)	Nov 24	1 day	Hoffman Michael BDirector	PPurchase	+39.2K	$4.08	+$159.9K	+1.6%2.53M after	Amended4 lots
Nov 21, 2025 (view filing)	Nov 21	Same day	Hoffman Michael BDirector	PPurchase	+20.0K	$3.50	+$69.9K	+0.8%2.49M after	2 lots
Nov 18, 2025 (view filing)	Nov 14	4 days	Hoffman Michael BDirector	PPurchase	+15.0K	$2.11	+$31.6K	+0.6%2.47M after
Nov 12, 2025 (view filing)	Oct 28	15 daysLate	Maccecchini Maria-LuisaPresident & CEO	PPurchase	+97.6K	$2.05	+$200.0K	+8.8%1.21M after
Nov 12, 2025 (view filing)	Oct 28	15 daysLate	Hoffman Michael BDirector	PPurchase	+975.6K	$2.05	+$2.00M	+65.9%2.46M after

Top 10 13F holders, Q2 2026

See all 61 holders

The largest institutional positions in Annovis Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding ANVS in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Empery Asset Management, LP	2,401,476	$4.47M	5.17%	+2,401,476	New
Marshall Wace, LLP	1,842,339	$3.43M	0.00%	+654,840+55.1%	Added
Vanguard Capital Management LLC	1,647,322	$3.06M	0.00%	+774,941+88.8%	Added
Tudor Investment Corp Et Al	1,357,134	$2.52M	0.01%	+1,357,134	New
Renaissance Technologies LLC	1,002,200	$1.86M	0.00%	+654,600+188.3%	Added
Two Sigma Investments, LP	579,571	$1.08M	0.00%	−48,088−7.7%	Reduced
Geode Capital Management, LLC	283,817	$528.1K	0.00%	+36,304+14.7%	Added
BlackRock, Inc.	249,856	$464.7K	0.00%	+110,323+79.1%	Added
Citadel Advisors LLC	243,682	$453.2K	0.00%	+243,682	New
Vanguard Fiduciary Trust Co	177,530	$330.2K	0.00%	+45,488+34.4%	Added

Holders of 5% or more of ANVS

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Annovis Bio, Inc..

Largest holders of ANVS from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Highbridge Capital Management LLC	13G	6.10%2.78M shares	New	Aug 14, 20261 filing	Aug 14, 2026	SEC